Becker muscular dystrophy (BMD) is a milder X-linked dystrophin deficiency than Duchenne, caused by in-frame mutations that allow production of a shortened but partially functional dystrophin protein. Onset and progression vary widely — some men remain ambulatory into their 40s while others lose mobility in their 20s — and heart involvement is a leading cause of complications.
What's actually going on in research
Unlike Duchenne, BMD has no approved disease-modifying therapy, making it a target for treatments developed for DMD that may also benefit Becker patients. Trials are testing exon-skipping drugs, micro-dystrophin gene therapy, and utrophin upregulators. Cardiac monitoring and heart failure treatment are a focus given that cardiomyopathy often progresses independent of skeletal muscle severity in BMD.
Gene therapy extension
Micro-dystrophin gene replacement therapies being developed for DMD are being evaluated in BMD patients with advanced disease, where boosting dystrophin levels may slow further decline.
Utrophin upregulation
Small molecules that increase production of utrophin — a functional substitute for dystrophin — are in trials and could benefit all dystrophin-deficiency patients regardless of specific mutation.
Cardiac management
Trials are studying angiotensin-converting enzyme inhibitors, beta-blockers, and other agents to slow cardiomyopathy progression in BMD, where heart disease often drives morbidity independently of muscle status.
What to know before you search
Eligibility depends on the specific dystrophin mutation, cardiac function, ambulatory status, and whether the patient has already been enrolled in DMD gene therapy trials.
What types of trials are currently open
- Gene therapy trials — Testing AAV micro-dystrophin delivery in Becker patients with functional decline.
- Utrophin upregulator trials — Evaluating small molecules that increase the natural dystrophin substitute protein across mutation types.
- Cardiac trials — Studying drugs to prevent or slow cardiomyopathy in Becker muscular dystrophy.
- Exon-skipping trials — Testing antisense approaches in Becker patients amenable to exon skipping based on their specific mutations.
- Natural history trials — Characterizing disease progression and biomarkers to support future drug development.
Recently added Becker Muscular Dystrophy trials
DMD Gene Variants and Cardiac Dysfunction in Young Males With Dystrophinopathies
The goal of this observational study is to investigate whether the type, location, and extent of pathogenic variants in the DMD gene are associated with cardiac dysfunction in male children, adolescents, and young adults with dystrophinopathies. The study also evaluates whether cardiac biomarkers and electrocardiographic findings can facilitate the early identification of cardiac involvement. Participants will undergo electrocardiography, blood sampling for cardiac biomarker assessment, and transthoracic echocardiography, with cardiac dysfunction evaluated using ejection fraction (EF) and global longitudinal strain (GLS).
Invasive Home Ventilation in Denmark
The aim of this study is to describe national trends over the past 10 years in patients receiving invasive home mechanical ventilation (HMV) in Denmark. This includes indications for invasive HMV, diagnostic groups, and one-year mortality.
Find Becker Muscular Dystrophy trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.